[Webinar] How to better optimize an oncology drug discovery program
Register for this webinar discussing how conventional and innovative integrated technological skills should be incorporated into an oncology program.
Read more Our experts support you in understanding and evaluating the role of the microbiome in the discovery and development of new therapeutic molecules. We analyse its influence and effects on the efficacy of treatments in our preclinical in vitro and in vivo proof-of-concept models in oncology, immuno-oncology, inflammation and for COVID-19.
SOLO Microbiome gives you the possibility to mimic the microbial imbalance or dysbiosis observed in different pathologies such as cancer, gastrointestinal, dermal inflammations, and metabolic disorders, in experimental models.
We guide you in your research and discovery programs of new therapies based on microbial agents aimed at modulating the microbiota and the immune response accordingly. We can also study the impact of the microbiome on the metabolism of your therapeutics.
You will have access to expertise and technical capabilities specific to the study of the microbiome, such as culture and preparation of aerobic and anaerobic bacteria, detection and identification of bacteria, their localization by imaging studies in the animal organism, transfer of human or animal feces and analysis of the global microbiome.